Menopausia y síndrome metabólico

  • Alejandro Pinzon Tovar Universidad Surcolombiana
  • Carlos Celemin Universidad del Tolima
Palabras clave: síndrome metabólico, menopausia, obesidad

Resumen

El incremento en el contenido de grasa visceral abdominal y el aumento en la resistencia a insulina de la mujer post menopáusica son eventos principales en el desarrollo del síndrome metabólico; que se define como un grupo de alteraciones clínicas que incluye la obesidad, trastornos hiperglicemicos, hipertensión y dislipidemia1. Todos estos trastornos aumentan el riesgo de enfermedad cardiovascular, siendo una de las principales causas de morbi-mortalidad en las mujeres mayores de 55 años en los países occidentales. Los estrógenos endógenos parecen ser cardio protectores y la deficiencia estrogénica de la menopausia se asocia a un sin número de alteraciones metabólicas que incrementan el riesgo cardiovascular. En esta revisión se abordan los principales tópicos relacionados con el síndrome metabólico así como su tratamiento durante la menopausia y modificación del estilo de vida.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Alejandro Pinzon Tovar, Universidad Surcolombiana
MD. Internista, Universidad Surcolombiana Neiva. Endocrinólogo Universidad Militar Nueva Granada. Médico Internista y Endocrinólogo del Hospital Universitario Hernando Moncaleano Perdomo Neiva. Médico Internista y Endocrinólogo de ENDHO Colombia Neiva. Miembro numero ACE. Presidente capitulo eje cafetero (2014)
Carlos Celemin, Universidad del Tolima
MD. General, Universidad del Tolima. Medico general Clínica Uros Neiva. Medico general de ENDHO Colombia Neiva.

Referencias

Expert panel on detection evaluation, and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2558.

Liberopoulos, E. N. Diagnosis and management of the metabolic syndrome in obesity. Obesity reviews 6, 2005; 283-296.

Carr, M. C. The Emergence of the Metabolic Syndrome with Menopause. J Clin Endocrinol Metab 2003; 88: 2404-2411.

Kim, H. M. The Effect of Menopause on the Metabolic Syndrome Among Korean Women. Diabetes Care 2007; 30: 701-706.

Chu, M. C. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. American Journal of Obstetrics and Gynecology. 2006; 194: 100-4.

Bulun, S. E. The physiology and pathology of the female reproductive axis. In: Larsen, P. Williams textbook of. Endocrinology. Tenth edition. Cap. 16. 2003; 587-664.

WU, J. M. Ovarian Aging and Menopause: Current Theories, Hypotheses, and Research Models. Exp Biol Med 2005; 203: 818-828.

Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al, for the STRAW+10 Collaborative Group. Executive summary of the stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause: The Journal of The North American Menopause Society 2012; 97(4):1159-68

López, J. C. Síndrome metabólico e infertilidad. En: Pérez, L. E. Infertilidad y endocrinología reproductiva. 3ra Edición. Basada en evidencias. Cap. 18. 2007. 267-278.

Mauriége, P. Subcutaneous Adipose Tissue Metabolism at Menopause: Importance of Body Fatness and Regional Fat Distribution. J Clin Endocrinol Metab 2000; 85: 2446-2454.

Ardila, E. Consenso Colombiano de Síndrome Metabó- lico. Asociación Colombiana de Endocrinología. 2006.

POSITION STATEMENT. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause: The Journal of the North American Menopause Society. Vol. 15, No. 4, 2008; pp. 584/602.

Tamakoshi. K. The transition to menopause reinforces adiponectin production and its contribution to improvement of insulin-resistant state. Clinical Endocrinology. 2007;66:65-71.

Dubey, R. K. Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. Cardiovascular Research. 2005;66: 295-306.

Coylewright, M. Menopause and Hypertension: An AgeOld Debate. Hypertension. 2008; 51:952-959.

Kopelman, P. Health risks associated with overweight and obesity. Obesity reviews 8 (Suppl. 1) 2007;13-17.

Hu, F. B. Adiposity as Compared with Physical Activity in Predicting Mortality among Women. N Engl J Med. 2004; 351:2694-703.

Cho, J. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause. 2008; 15(3): 524-529.

Sowers, M. Changes in Body Composition in Women over Six Years at Midlife: Ovarian and Chronological Aging. J Clin Endocrinol Metab 2007;92:895-901.

Hadji, P. The influence of menopause and body mass index on serum leptin concentrations. European Journal of Endocrinology. 2000;143:55-60.

Santen RJ et al. 2010, Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism 95, Supplement 1:S1-S66

Hoene, M. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obesity reviews 9, 2008; 20–29.

Rachon, D. Effects of oestrogen deprivation on interleukin6 production by peripheral blood mononuclear cells of postmenopausal women. Journal of Endocrinology, 2002;172:387-395.

Pfeilschifter, J. Changes in Proinflammatory Cytokine Activity after Menopause. Endocrine Reviews 2002; 23: 90-119.

López Jaramillo et al. Latin American Consensus on Hypertension in patients with Diabetes type 2 and Metabolic Syndrome. Journal of Hypertension 2013; 31:223-238

James PA, Oprail S, Carter BL, Cushman WC, DennisonHimmelfarb C, Handler J et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adult: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.

American Diabetes Association. Standards of medical care in diabetes, 2015. Diabetes Care. 2015;38(Suppl 1): S1-S2.

Majmudar, N. G. Effects of the Menopause, Gender, and Estrogen Replacement Therapy on Vascular Nitric Oxide Activity. J Clin Endocrinol Metab 2000; 85: 1577-1583.

Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, Peverill. RE 2000 Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Tromb Vasc Biol 20:1404-1409.

Pines, A. Menopause and ischaemic stroke: basic, clinical and epidemiological considerations. The role of hormone replacement. Human reproduction update, 2002;8(2): 161-168.

Brown, T. Prevention of obesity: a review of interventions. Obesity reviews 8 (Suppl. 1), 2007; 127-130.

Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith Jr SC, Levy D, Watson K, Wilson PWF, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, Journal of the American College of Cardiology (2013), doi: 10.1016/j.jacc.2013.11.002.

Pinzón, A. Bases para realizar un protocolo de control glucémico. RFS, vol 4. N. 2. Julio – Diciembre 2012.

Publicado
2015-01-08
Cómo citar
Pinzon Tovar, A., & Celemin, C. (2015). Menopausia y síndrome metabólico. RFS Revista Facultad De Salud, 7(1), 69-76. https://doi.org/10.25054/rfs.v7i1.183
Sección
Artículos de revisión
Crossref Cited-by logo